A retrospective study assessing the assessing the efficacy and safety of Daratumumab-based regimens in patients with Monoclonal Gammopathy of renal significance
Latest Information Update: 19 Aug 2021
At a glance
- Drugs Bortezomib (Primary) ; Cyclophosphamide (Primary) ; Daratumumab (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary)
- Indications Paraproteinaemia
- Focus Adverse reactions; Therapeutic Use
- 20 Jul 2020 New trial record
- 21 Jun 2020 Results presented at the 25th Congress of the European Haematology Association